Finoriq research workspace
Acumen Pharmaceuticals, Inc. (ABOS) Institutional Holdings & 13F Ownership
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted. Review ABOS institutional holders, 13F ownership, and position changes on Finoriq.
Company Snapshot
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
- Company
- Acumen Pharmaceuticals, Inc. (ABOS)
- Ticker
- ABOS
- Market Cap
- $158.5M
- Latest Price
- $2.195
- Industry
- Biotech & Pharma
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.